Description
Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), developed by Professor Khavinson from vascular tissue extract analysis. It is the vascular endothelium-targeted member of the Khavinson series. KED shares its N-terminal motif with three other compounds in this catalog — Livagen (KEDA, liver), Prostamax (KEDP, prostate), and implicitly with Thymogen through the lysine-containing family — making Vesugen the starting point for KED-family structure-activity studies examining how C-terminal variation on the same scaffold affects tissue targeting. Documented endothelial research targets include endothelin-1 expression normalization, connexin Cx43 restoration, and SIRT1 activation. Vesugen has one of the better-characterized evidence bases in the specialty research peptide Khavinson catalog.
Key Characteristics
- KED family SAR position — Vesugen (KED) is the three-residue core from which Livagen (KEDA) and Prostamax (KEDP) extend by one additional C-terminal residue; researchers studying how C-terminal amino acid identity directs tissue targeting within the same N-terminal scaffold use this triplet as the comparative reference compound
- Endothelin-1 normalization is the primary documented endothelial endpoint — endothelin-1 is a potent vasoconstrictor elevated in atherosclerotic and restenotic vascular conditions; KED normalizes its expression in endothelial cell cultures derived from both normal and pathological tissue, giving Vesugen a specific mechanistic foothold in vascular disease biology research
- Connexin Cx43 restoration and SIRT1 activation add two additional endothelial research dimensions — Cx43 governs gap junction intercellular communication in the vascular wall; SIRT1 is an NAD+-dependent deacetylase linked to endothelial aging; both are independent of the endothelin-1 endpoint and extend Vesugen’s research relevance beyond a single signaling pathway
- Ki-67 upregulation in endothelial cell cultures suggests Vesugen modulates endothelial proliferative capacity — reduced Ki-67 expression and increased polyploid cell accumulation characterize aged endothelium; Vesugen reversal of these markers provides a cell-level aging biology endpoint distinct from the functional signaling targets above
- The evidence base is more extensive than most Khavinson bioregulators. They place Vesugen among the better-published compounds in this series, though independent Western replication and large-scale RCT data remain absent
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a tripeptide, Vesugen is susceptible to proteolytic degradation. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Vesugen?
Vesugen (KED) is a synthetic tripeptide bioregulator targeting vascular endothelial cells through direct intranuclear DNA binding. Its documented research targets include endothelin-1 expression normalization, connexin Cx43 gap junction restoration, SIRT1 activation, and endothelial Ki-67 modulation. It is the vascular endothelium representative of the Khavinson bioregulator series and shares its KED sequence core with Livagen (KEDA) and Prostamax (KEDP).
Why is Vesugen useful for KED-family structure-activity studies?
Vesugen (KED), Livagen (KEDA), and Prostamax (KEDP) share the same N-terminal KED tripeptide core but differ in C-terminal identity and tissue target. Vesugen targets the vascular endothelium, Livagen targets the liver and lymphocytes, and Prostamax targets the prostate tissue. This systematic C-terminal variation on a shared scaffold makes the KED family a model system for studying how minimal sequence changes redirect tissue targeting within the Khavinson bioregulator framework — a structure-activity research question that requires all three compounds to be examined comparatively.
How does Vesugen’s endothelin-1 research angle differ from other vascular research tools?
Endothelin-1 is a potent vasoconstrictor produced by endothelial cells and elevated in atherosclerotic and inflammatory vascular conditions. Unlike receptor antagonists that block endothelin receptor binding after the protein is expressed, Vesugen normalizes endothelin-1 gene expression at the transcriptional level through intranuclear peptide-DNA interaction. This upstream gene-regulatory approach produces a different experimental research context than receptor-blocking pharmacological tools and is specifically suited to models examining how endothelial gene expression programs change under pathological conditions.
